Ticagrelor versus clopidogrel in patients with acute coronary ...
Ticagrelor versus clopidogrel in patients with acute coronary ...
Ticagrelor versus clopidogrel in patients with acute coronary ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Primary and secondary efficacy endpo<strong>in</strong>ts<br />
from time of CABG<br />
CABG<br />
Characteristic<br />
Primary endpo<strong>in</strong>t<br />
CV death + MI + stroke<br />
<strong>Ticagrelor</strong><br />
(n=629)*<br />
Clopidogrel<br />
(n=629)<br />
10.5 12.6<br />
Hazard Ratio (95% CI)<br />
0.84 (0.60, 1.16)<br />
p-value<br />
0.29<br />
Secondary endpo<strong>in</strong>ts<br />
MI 5.9 5.6<br />
1.06 (0.66, 1.68)<br />
0.82<br />
CV death<br />
4.0 7.5<br />
0.52 (0.32, 0.85)<br />
0.009<br />
Stroke**<br />
2.1 1.7<br />
1.17 (0.53, 2.62)<br />
0.70<br />
All-cause mortality 4.6 9.2<br />
0.49 (0.32, 0.77)<br />
0.002<br />
Non-CV death 0.6 1.7<br />
0.35 (0.11, 1.11)<br />
0.07<br />
0.2<br />
0.5 1.0 2.0<br />
<strong>Ticagrelor</strong> better<br />
Clopidogrel better<br />
Patients could have had more than one type of endpo<strong>in</strong>t. Values are <strong>in</strong>cidences = number of events divided by n, not<br />
rates.<br />
*Three <strong>patients</strong> had miss<strong>in</strong>g values for the efficacy endpo<strong>in</strong>ts due to CABG after the censor<strong>in</strong>g date at 12 months<br />
**Results for hemorrhagic stroke: 0.0% (ticagrelor) and 0.2% (<strong>clopidogrel</strong>); non-hemorrhagic stroke: 2.1% and 1.6%
Change language